Ares Financial Consulting’s Mirum Pharmaceuticals MIRM Stock Holding History

Ares Financial Consulting’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16K	Buy	+27	New	+$2.71K	﹤0.01%	813

Other funds holding MIRM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Ares Financial Consulting's MIRM Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 27 shares worth $3.16K. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings.

101 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Ares Financial Consulting held 27 shares of Mirum Pharmaceuticals worth $3.16K as of Q2 2026.
Mirum Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
Mirum Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #813 holding.
101 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.